01386nas a2200193   4500000000100000008004100001260001600042653001700058653002600075653001900101653001700120653002200137100002500159700002000184245009900204856009200303520078300395022001401178       2025                            d  bElsevier BV10aBenznidazole10aChagas Cardiomyopathy10aChagas disease10aPosaconazole10aTrypanosoma cruzi1 aCrespillo-Andújar C1 aPerez-Molina JA00aThe importance of long-term follow-up data in Chagas disease: new challenges for old paradigms  uhttps://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(25)00311-8/abstract3 a<p>Chagas disease affects &gt;7 million people globally, with &gt;400 000 of them residing outside endemic regions. Approximately 70 000 of these cases are in Spain, making it the second non-endemic country with the highest estimated number of cases, after the United States [<a aria-label="Reference 1" href="https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(25)00311-8/abstract#">1</a>]. In recent decades, improvements in living conditions, globalization, and increased population mobility have significantly shaped the epidemiology of Chagas disease beyond endemic areas. Consequently, long-term follow-up data from cohorts in endemic regions—while historically valuable—may no longer accurately reflect the current landscape of the disease&nbsp;</p>
  a1198-743X